1. Introduction
Bisphosphonates (BP) are antiresorptive drugs used in the management of conditions as diverse as osteoporosis and metastatic bone diseases. These drugs are widely administered and generally well tolerated by patients. In 2003, Marx et al. [ 1 ] first reported a nonhealing necrosis of the maxillofacial region in some patients taking BPs.
In the last decade researchers have discovered that BPs not exclusively cause osteonecrosis of jaws, as other drugs, such as antiresorptive (bone-targeted) agents like denosumab, but also were found to cause it. In addition, monoclonal antibodies able to bind and selectively inhibit VEGF-A, specifically mTOR inhibitors, can also cause osteonecrosis of the jaw [ 2 – 6 ].
For this reason, in 2014 the bisphosphonate-related osteonecrosis of the jaw (BRONJ) nomenclature was changed by the position paper of the American Association of Oral and Maxillofacial Surgeons (AAOMS) special committee on Medication-Related Osteonecrosis of the Jaws (MRONJ) [ 7 ]. The term “medication-related osteonecrosis of the jaws” (MRONJ) refers to a complication associated with groups of medications, such as antiangiogenic or antiresorptive drugs [ 8 ]. These medications can have different indications depending on their mode of administration (Tables 1 and 2 ) [ 9 , 10 ].
According to AAOMS, MRONJ is defined as an exposition of necrotic bone in the oral cavity lasting more than 8 weeks, in patients who took antiresorptive or antiangiogenic drugs; these patients have not been exposed to head and neck radiotherapy, nor show signs of bone metastases in the maxillofacial region [ 7 ].
A number of systemic risk factors have been associated with increased likelihood of MRONJ; they are summarised in Table 3 [ 11 , 12 ].
Dental extraction or other surgical procedures such as apicectomies or cystectomies have been found in between 52% and 80% of MRONJ patients' medical history [ 13 – 15 ].
During the last decade AAOMS has revised and proposed a clinical staging classification system of the disease in an attempt to guide clinicians and surgeons to an appropriate therapeutic approach ( Table 4 ).
The management of MRONJ is reported to be very challenging and with no current “gold standard”. Published studies have reported a number of approaches to treatment, with widely varying success rates, ranging from no or limited to radical surgery. The ideal outcome is total eradication of MRONJ along with an improvement of patients' quality of life through pain release and infection management [ 16 ].
Conservative treatment was considered to be partially successful, with resolution reported in only 50% of cases; particular concerns have been reported on MRONJ at clinical stages II and III [ 17 – 19 ]. In case conservative treatments fail, surgical approaches like local debridement, osteoplasty, and segmental osteotomy are normally performed [ 20 , 21 ].
However, patients that show evidence of MRONJ stage III with severe pain, infection, pathologic fracture, extra-oral fistula, or osteolysis extending to the inferior border of the mandible require an invasive type of surgery which might result in a disabling outcome [ 7 , 16 , 22 ].
The absence of a well-established surgical treatment protocol in scientific literature makes it difficult to conduct therapy in advanced cases of the disease.
Up to date, there is no standard treatment for MRONJ associated with antiresorptive and antiangiogenic therapies. Several treatment options have been described since MRONJ was first reported. Although the initial stages of MRONJ seem to respond quite well to conservative treatments or limited bone debridement if conservative treatment fails, the treatment for stage III lesions remains still controversial [ 23 , 24 ].
The objective of this review is to evaluate the outcome of free vascularised osseous tissue transfer and/or osteofasciocutaneous free flap as treatment for patients affected by MRONJ stage III. Systematic reviews have been already published. However, these reviews were not performed in a standardised manner or did not follow strict criteria. Moreover the previous reviews did not consider antiangiogenic drugs in the search criteria. This has resulted in lack of quality assurance, summarised in Table 5 [ 25 – 27 ]. This review aims to improve the quality of previous research and expand on the current data available.
2. Materials and Methods
This systematic review was performed according to PRISMA guidelines [ 44 ].
The following the databases were used for the review: PubMed/MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL). A three-stage screening approach was used to ensure precision and the quality of the search. The screening of titles and abstracts was carried out independently by three authors (AH, UH, and RS) to eliminate any irrelevant materials (i.e., reviews, animal studies, nonclinical studies, and studies that did not report on patients undergoing to free tissue graft). Disagreements were resolved by discussion.
A data screening and abstraction form was used to
(1) verify the study eligibility derived from the above inclusion/exclusion criteria,
(2) carry out the methodological quality assessment,
(3) extract data on study characteristics and outcomes for the included studies.
The authors of any studies eligible for inclusion in the review, yet without sufficient information, were contacted directly ( Figure 1 ).
2.1. Criteria for Inclusion in This Review
2.1.1. Types of Studies
The types of studies included in the research strategy were published or unpublished randomised control trials, case-controlled trials, case series, retrospective studies, and case reports. Papers were obtained from January 2003 to June 2017. Animal studies and those including patients with previous history of radiation therapy to the head and neck regions were excluded. No language restrictions were imposed to the search.
2.1.2. Types of Participants
The review considered studies involving patients who developed MRONJ and subsequently underwent free vascularised osseous tissue transfer and/or osteofasciocutaneous free flap reconstruction. No restriction of age, gender, or ethnic origin was applied. There was no restriction on the minimum number of patients included in the studies.
2.1.3. Types of Interventions
Only free vascularised osseous tissue transfer and/or osteofasciocutaneous free flap reconstruction were considered.
2.1.4. Types of Outcome Measures
Primary Outcomes . Primary outcome measures of the review included the success rate of free flap without any restrictions in follow-up. The other considered measures were the frequency of MRONJ recurrence in the free flap or in the surgical residual jaw bone.
Secondary Outcomes . The secondary measures of the review entailed perioperative complications and those at follow-up, including the most common cause of the MRONJ and the time during which the patient was treated with the antiresorptive or antiangiogenic drugs prior ONJ.
2.2. Data Extracted
Data extracted from the eighteen studies included number of patients, patient sex, and age, predisposing factors for, and localisation of, MRONJ, type of antiangiogenic or antiresorptive drugs and their cumulative dose, clinical indications for the drug or combined therapy, extent of the surgical excision, type of free vascularised tissue reconstruction, free flap failure, immediate complications, follow-up time, and MRONJ recurrence.
All selected papers were carefully read to identify author(s), year of publication, study design, population and treatment characteristics, and number of patients with recurrent MRONJ.
In case of missing information, we contacted the authors and gave them 6 weeks to reply. If the information was still missing we then indicated the missing data as “Not Reported (NR)” in the text and in the tables.
3. Results
Results were expressed in descriptive statistics. No randomised controlled clinical trials or case-controlled studies comparing free flap reconstruction after resection in MRONJ patients were found. A total number of 18 articles we included in the study. All the published dates were described in case report (no. 6) and case series (no. 12) from 2008 to 2017 ( Table 6 ). A total of 83 patients, 47 females (56.62%), 19 males (22.89%), and missing information for 20.49% (NR) of the cases, were treated using vascularised osseous tissue transfer and/or osteofasciocutaneous free flap reconstruction.
The most common indications for antiresorptive or antiangiogenic treatment were breast cancer (28.91%), multiple myeloma (22.89%), osteoporosis (14.45%), prostate cancer (9.63%), lung cancer (2.40%), myeloid-leukemia and osteoporosis (1.20%), pain syndrome (1.20%), and NR in the 19.32% of the cases ( Table 7 ). The most common site for MRONJ was the mandible 97.59% and 2.41% in the maxilla ( Table 8 ).
Zoledronate was responsible for the majority of the MRONJ with 42.16 %, then pamidronate 7.22%, alendronate 8.43%, ibandronate 2.40%, and etidronate 1.20%. A combination of the following drugs and the relative incidence percentage were also found responsible:
zoledronate and pamidronate (13.25%);
zoledronate and clodronate (1.20%);
zoledronate and denosumab (1.20%);
pamidronate and denosumab (1.20%);
alendronate, risedronate, and pamidronate (1.20%).
A total of 20.54% patients presented missing information with regard to the type of drug used.
69.90% of the cases missed information on the causes of the MRONJ.
The most commonly utilised vascularised free flap reconstruction was fibula free flap (81.92%), followed by iliac crest (12.04%) and scapula (6.02%).
The most frequent type of resection was subtotal (32.53%), followed by segmental (26.50%) and partial (2.40%). However a large percentage of missing data was found regarding the type of resection (NR 38.57%) ( Table 9 ).
The patients were followed for a period of time ranging from 2 weeks up to 99 months.
Radiographic imaging with CT, cone-beam, and/or orthopantomogram was obtained during follow-up in 95% of the cases.
At follow-up and after free flap reconstruction, recurrence of MRONJ (6.02%) was observed in 5 patients: two of the patients (2.40%) on the contralateral unresected part of the jaw, other two patients (2.40%) on the margin of the resection, and one patient (1.20%) on the grafted flap. The overall free flap failure rate registered was 3.61% ( Table 10 ).
3.1. Review Quality Assessment Data
All the studies and data extraction included in the systematic review were qualitative and the risk of bias assessed independently by the authors. The authors used the CARE Checklist for case report and the Modified Delphi Checklist for the case series studies.
In the six case report studies, we identified lack of clarity in many of the thirteen domains, with missing information. We found that the lack of clarity was predominantly on follow-up and diagnostic procedure at the time of follow-up. Hence we concluded the level of bias to be high for all the included case report studies.
In the twelve case series studies, we reported a consistent lack of clarity in some of the seven domains, predominantly regarding the outcome measurement methods. Moreover, we identified some missing information in few other domains; hence we considered the level of bias to be high for all studies
We contacted the authors of these clinical cases to clarify this bias; however we were unable to recover the missing information.
4. Discussion
Some antiresorptive drugs such as BP or denosumab have demonstrated to improve the quality of life in patients affected by bone metastasis, osteoporosis, osteopenia, and Paget disease. Additionally, a new antiangiogenic therapy has been successfully used for specific cancer treatments. However, this has remarkably increased the risk of developing MRONJ. This risk is greater in patients who require a higher administration dosage and an intake period greater than 2 years [ 14 , 45 , 46 ].
Moreover, literature has reported that demography, corticosteroid therapy, systemic factors, and genetic factors have been associated with MRONJ. A recent review report showed a wide-ranging MRONJ incidence from 0 to 27.5% in individuals exposed to intravenous BPs, with a mean incidence of 7%, whereas it ranges from 0.1% to 0.06% in oral administrations [ 47 – 49 ].
Etiopathogenesis of MRONJ is not yet fully understood.
Although no gold standard is currently available for the treatment of jaw osteonecrosis, a number of studies debate which MRONJ stage benefits the most from surgical therapy [ 24 , 50 ]. In general, for early stages of the disease (MRONJ 0 and I) conservative treatments might be sufficient; surgical treatment should be restricted to advanced stages (MRONJ II and III) or after failure of conservative treatments [ 7 , 50 ].
The majority of researches as well as AAOMS consider conservative treatments as the treatment of choice of MRONJ.
However, there is not a robust evidence from clinical trials as treatment recommendations mostly come from expert opinions and are, therefore, characterised by a low level of evidence [ 24 , 47 ].
The authors of the 2009 AAOMS position statement recommend reserving resection and immediate reconstruction to patients with stage III of the disease; however, positive outcomes have been noted in patients with stages II and III. Having said that no recommendations were given on which type of reconstruction was to be considered the most predictable [ 47 ]. The benefits of surgical management of MRONJ have been extensively debated in literature and radical surgery seems to offer more predictable and curative results. However, surgical treatment of early stages of MRONJ remains controversial [ 47 , 50 – 52 ].
Aggressive radical surgery is offered only to symptomatic patients with extensive osteonecrosis, including those who have previously failed conservative treatments [ 41 ].
This review has indicated that surgical therapy may represent a treatment option for patients affected by MRONJ stage III resulting in high success rates. Mucke et al. and Caldroney et al. have documented excellent outcomes in treating patient affected by MRONJ stage III in large cohort studies [ 30 , 43 ]. Since 2008 microvascular reconstruction of the jaw has been documented as a viable option for MRONJ. This systematic review confirmed that microsurgical reconstruction therapy represents a feasible alternative in case of treatment escalation.
Even though the majority of papers included in this study were case reports and small case studies, the outcome of free flap treatment has been promising with a significant low recurrence of MRONJ and minimal surgical complications [ 25 , 26 , 28 – 43 ].
The MRONJ recurrence rate found by this systematic review was 6.02% (5 patients). The predominant recurrence sites were the contralateral unresected part of the jaw (2 cases) and the margin of the resection (2 cases), both bearing an overall recurrence rate of 2.40%. Just one case of recurrence was found on the vascular reconstruction.
Infection was the most frequent complication found with 6.02% incidence. The overall free flap success rate was 96.39%. Three free flaps failed during a follow-up period ranging from 2 weeks up to 99 months.
Amongst all the types of reconstruction, free flap fibula was the most chosen, followed by iliac crest and scapula with success rates, respectively, of 97.60%, 98.80%, and 100%.
Antiresorptive drugs were explicitly discontinued in only three studies out of the eighteen, while no mention was reported in the remaining studies [ 31 , 33 , 41 ]. It is unclear if the discontinuation strategy leads to a better surgical outcome due to the long skeletal life of some antiresorptive drugs.
In line with the growing body of literature, our findings confirm positive results in treating patients with MRONJ using free flaps microvascular reconstruction. In order to obtain a possible resolution of MRONJ, patients with reasonable life expectancy should be considered for microvascular flap reconstruction after aggressive resection of the diseased bone.
5. Conclusion
MRONJ is a significant adverse effect amongst patients under antiresorptive agents. Although MRONJ pathogenesis remains unclear, significant progress has been made with respect to the diagnosis and staging of the disease, as well as with risk-reduction strategies and treatments. This systematic review based on multiple-reviewer quality assessment criteria was only able to select articles that meet Level 4 of the Oxford Evidence-based medicine scale. Due to the nature of the MRONJ incidence and the critical condition of the patients affected by the primary disease, it is difficult to improve the quality of evidence unless a common effort is applied. Therefore, the authors believe that additional quality studies, such as control multicentre studies or case-controlled studies, are necessary to support the hypothesis of this study.
Conflicts of Interest
This study was not supported by any company and all the authors have not conflicts of interest.
Authors' Contributions
All the authors of this manuscript have substantial contributions to the conception or design of the work; to the acquisition, analysis, or interpretation of data for the work; to draft of the paper and revising it critically and finally approved the version to be published.
1 Marx R. E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic Journal of Oral and Maxillofacial Surgery 2003 61 9 1115 1117 10.1016/S0278-2391(03)00720-1 2-s2.0-0042861578 12966493
2 Ruggiero S. L. Mehrotra B. Rosenberg T. J. Engroff S. L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases Journal of Oral and Maxillofacial Surgery 2004 62 5 527 534 10.1016/j.joms.2004.02.004 2-s2.0-2142817155 15122554
3 Sivolella S. Lumachi F. Stellini E. Favero L. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease Anticancer Reseach 2013 33 5 1793 1798 2-s2.0-84878187271 23645723
4 Santos-Silva A. R. Belizário Rosa G. A. Castro Júnior G. D. Dias R. B. Prado Ribeiro A. C. Brandão T. B. Osteonecrosis of the mandible associated with bevacizumab therapy Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2013 115 6 e32 e36 2-s2.0-84878304679 10.1016/j.oooo.2013.02.001 23567260
5 Ramirez L. Lopez R. M. Casanas E. New non-bisphosphonate drugs that produce osteonecrosis of the jaws Oral Health and Preventive Dentistry 2015 13 385 393 25884045 10.3290/j.ohpd.a34055
6 Brunello A. Saia G. Bedogni A. Scaglione D. Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma Bone 2009 44 1 173 175 2-s2.0-57449100050 10.1016/j.bone.2008.08.132 18849018
7 Ruggiero S. L. Dodson T. B. Fantasia J. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update Journal of Oral and Maxillofacial Surgery 2014 72 10 1938 1956 10.1016/j.joms.2014.04.031 25234529
8 Rosella D. Papi P. Giardino R. Cicalini E. Piccoli L. Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines Journal of International Society of Preventive and Community Dentistry 2016 6 2 97 104 2-s2.0-85006263546 10.4103/2231-0762.178742 27114946 PMC4820581
9 Nussbaum S. R. Younger J. Vandepol C. J. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages American Journal of Medicine 1993 95 3 297 304 2-s2.0-0027214135 10.1016/0002-9343(93)90282-T 8368227
10 Berenson J. R. Hillner B. E. Kyle R. A. American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma Journal of Clinical Oncology 2002 20 17 3719 3736 10.1200/JCO.2002.06.037 2-s2.0-0036729485 12202673
11 Campisi G. Fedele S. Fusco V. Pizzo G. Di Fede O. Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents Future Oncology 2014 10 2 257 275 2-s2.0-84893820808 10.2217/fon.13.211 24490612
12 Khan A. Morrison A. Ruggiero S. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus Journal of Bone and Mineral Research 2015 30 1 3 23 25414052 10.1002/jbmr.2405
13 Vahtsevanos K. Kyrgidis A. Verrou E. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw Journal of Clinical Oncology 2009 27 32 5356 5362 10.1200/jco.2009.21.9584 2-s2.0-73849148160 19805682
14 Saad F. Brown J. E. Van Poznak C. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Annals of Oncology 2012 23 5 1341 1347 10.1093/annonc/mdr435 2-s2.0-84860467736 21986094
15 Heufelder M. J. Hendricks J. Remmerbach T. Frerich B. Hemprich A. Wilde F. Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2014 117 6 e429 e435 2-s2.0-84901365119 10.1016/j.oooo.2012.08.442 23182374
16 Weber J. B. B. Camilotti R. S. Ponte M. E. Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review Lasers in Medical Science 2016 31 6 1261 1272 2-s2.0-84962250977 10.1007/s10103-016-1929-4 27025860
17 Pautke C. Bauer F. Otto S. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: First clinical results of a prospective pilot study Journal of Oral and Maxillofacial Surgery 2011 69 1 84 91 2-s2.0-78650288904 10.1016/j.joms.2010.07.014 20971542
18 Montebugnoli L. Felicetti L. Gissi D. B. Pizzigallo A. Pelliccioni G. A. Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2007 104 4 473 477 2-s2.0-34648827431 10.1016/j.tripleo.2007.01.008 17482847
19 van den Wyngaert T. Claeys T. Huizing M. T. Vermorken J. B. Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome Annals of Oncology 2009 20 2 331 336 10.1093/annonc/mdn630 2-s2.0-60549109454 18953067
20 Klingelhöffer C. Zeman F. Meier J. Reichert T. E. Ettl T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws Journal of Cranio-Maxillo-Facial Surgery 2016 44 10 1694 1699 2-s2.0-85002658206 10.1016/j.jcms.2016.08.001 27591091
21 Atalay B. Yalcin S. Emes Y. Bisphosphonate-related osteonecrosis: Laser-assisted surgical treatment or conventional surgery? Lasers in Medical Science 2011 26 6 815 823 2-s2.0-83255185211 10.1007/s10103-011-0974-2 21809068
22 Otto S. Schreyer C. Hafner S. Bisphosphonate-related osteonecrosis of the jaws - Characteristics, risk factors, clinical features, localization and impact on oncological treatment Journal of Cranio-Maxillo-Facial Surgery 2012 40 4 303 309 2-s2.0-84860696738 10.1016/j.jcms.2011.05.003 21676622
23 Voss P. J. Joshi Oshero J. Kovalova-Müller A. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: Technical report and follow up of 21 patients Journal of Cranio-Maxillo-Facial Surgery 2012 40 8 719 725 2-s2.0-84869491559 10.1016/j.jcms.2012.01.005 22336489
24 Marx R. E. Sawatari Y. Fortin M. Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment Journal of Oral and Maxillofacial Surgery 2005 63 11 1567 1575 10.1016/j.joms.2005.07.010 2-s2.0-27344453813 16243172
25 Vercruysse H. Backer T. D. Mommaerts M. Y. Outcomes of osseous free flap reconstruction in stage III bisphosphonate-related osteonecrosis of the jaw: Systematic review and a new case series Journal of Cranio-Maxillo-Facial Surgery 2014 42 5 377 386 2-s2.0-84902126689 10.1016/j.jcms.2014.01.005 24642091
26 Neto T. Horta R. Balhau R. Resection and microvascular reconstruction of bisphosphonate-related osteonecrosis of the jaw: The role of microvascular reconstruction Head & Neck 2016 38 8 1278 1285 2-s2.0-84978919512 10.1002/hed.24395 27159622
27 Sacco R. Sacco G. Acocella A. Sale S. Sacco N. Baldoni E. A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosis Journal of Applied Oral Science 2011 19 4 293 300 2-s2.0-80053182824 10.1590/S1678-77572011000400001 21952925 PMC4223777
28 Engroff S. L. Coletti D. Bisphosphonate related osteonecrosis of the palate: report of a case managed with free tissue transfer Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2008 105 5 580 582 2-s2.0-42949136882 10.1016/j.tripleo.2007.11.025 18442742
29 Ferrari S. Bianchi B. Savi A. Fibula Free Flap With Endosseous Implants for Reconstructing a Resected Mandible in Bisphosphonate Osteonecrosis Journal of Oral and Maxillofacial Surgery 2008 66 5 999 1003 2-s2.0-41949132378 10.1016/j.joms.2007.06.631 18423292
30 Mücke T. Haarmann S. Wolff K.-D. Hölzle F. Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction Journal of Cranio-Maxillo-Facial Surgery 2009 37 5 291 297 2-s2.0-67349160804 10.1016/j.jcms.2008.12.004 19179088
31 Nocini P. F. Saia G. Bettini G. Vascularized fibula flap reconstruction of the mandible in bisphosphonate-related osteonecrosis European Journal of Surgical Oncology 2009 35 4 373 379 2-s2.0-60849093475 10.1016/j.ejso.2008.05.002 18562154
32 Seth R. Futran N. D. Alam D. S. Knott P. D. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws The Laryngoscope 2010 120 11 2165 2171 10.1002/lary.21062 2-s2.0-78349285903 20824743
33 Bedogni A. Saia G. Bettini G. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis Oral Oncology 2011 47 5 420 424 2-s2.0-79956202286 10.1016/j.oraloncology.2011.02.024 21439892
34 Pautke C. Otto S. Reu S. Bisphosphonate related osteonecrosis of the jaw - Manifestation in a microvascular iliac bone flap Oral Oncology 2011 47 5 425 429 2-s2.0-79956219064 10.1016/j.oraloncology.2011.03.022 21478047
35 Bittner T. Lorbeer N. Reuther T. Böhm H. Kübler A. C. Müller-Richter U. D. A. Hemimandibulectomy after bisphosphonate treatment for complex regional pain syndrome: A case report and review on the prevention and treatment of bisphosphonate-related osteonecrosis of the jaw Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2012 113 1 41 47 2-s2.0-84862570372 10.1016/j.tripleo.2011.01.017 22677690
36 Ghazali N. Collyer J. C. Tighe J. V. Hemimandibulectomy and vascularized fibula flap in bisphosphonate-induced mandibular osteonecrosis with polycythaemia rubra vera International Journal of Oral and Maxillofacial Surgery 2013 42 1 120 123 2-s2.0-84872037301 10.1016/j.ijom.2012.03.019 22520725
37 Hanasono M. M. Militsakh O. N. Richmon J. D. Rosenthal E. L. Wax M. K. Mandibulectomy and free flap reconstruction for bisphosphonate-related osteonecrosis of the jaws JAMA Otolaryngology - Head and Neck Surgery 2013 139 11 1135 1142 2-s2.0-84892428289 10.1001/jamaoto.2013.4474 24051498
38 Horta R. Monteiro D. Neto T. Microsurgical reconstruction for radiation- and bisphosphonate-induced mandible osteonecrosis based on patient-specific physiopathologic mechanisms The Journal of Craniofacial Surgery 2014 25 5 1793 1796 2-s2.0-84914688732 10.1097/SCS.0000000000000949 25098576
39 Spinelli G. Torresetti M. Lazzeri D. Microsurgical reconstruction after bisphosphonate-related osteonecrosis of the jaw: Our experience with fibula free flap The Journal of Craniofacial Surgery 2014 25 3 788 792 2-s2.0-84900828456 10.1097/SCS.0000000000000833 24820708
40 Kim H. Hwang J. Ahn K. Fibula Free Flap for Mandibular Reconstruction using Simulation Surgery in Bisphosphonate related Osteonecrosis of the Jaw Journal of International Society for Simulation Surgery 2015 2 1 1 6 10.18204/JISSiS.2015.2.1.001
41 Mücke T. Jung M. Koerdt S. Mitchell D. A. Loeffelbein D. Kesting M. R. Free flap reconstruction for patients with bisphosphonate related osteonecrosis of the jaws after mandibulectomy Journal of Cranio-Maxillo-Facial Surgery 2016 44 2 142 147 2-s2.0-84956695421 10.1016/j.jcms.2015.11.015 26752221
42 Sotsuka Y. Fujiwara T. Kawai K. Nishimoto S. Kakibuchi M. Bilateral Maxillary Reconstruction Using Fibular Flap in Bisphosphonate-related Osteonecrosis Plastic and Reconstructive Surgery - Global Open 2016 4 9 p. e1045 10.1097/GOX.0000000000001045 PMC5055021 27757355
43 Caldroney S. Ghazali N. Dyalram D. Lubek J. E. Surgical resection and vascularized bone reconstruction in advanced stage medication-related osteonecrosis of the jaw International Journal of Oral and Maxillofacial Surgery 2017 46 7 871 876 2-s2.0-85013395213 10.1016/j.ijom.2017.01.023 28233647
44 Liberati A. Altman D. G. Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration British Medical Journal 2009 339 b2700 10.1136/bmj.b2700 2-s2.0-68549101842 PMC2714672 19622552
45 Henry D. H. Costa L. Goldwasser F. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma Journal of Clinical Oncology 2011 29 9 1125 1132 2-s2.0-79952761418 10.1200/JCO.2010.31.3304 21343556
46 Fung P. P. L. Bedogni G. Bedogni A. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study Oral Diseases 2017 23 4 477 483 2-s2.0-85014577602 10.1111/odi.12632 28039941
47 Ruggiero S. L. Dodson T. B. Assael L. A. Landesberg R. Marx R. E. Mehrotra B. American association of oral and maxillofacial surgeons postion paper on bisphosphonate-related osteonecrosis of the jaws Journal of Oral and Maxillofacial Surgery 2009 67 5, supplement 1 2 12 10.1016/j.joms.2009.01.009 2-s2.0-64649105333 19371809
48 Kühl S. Walter C. Acham S. Pfeffer R. Lambrecht J. T. Bisphosphonate-related osteonecrosis of the jaws—a review Oral Oncology 2012 48 10 938 947 10.1016/j.oraloncology.2012.03.028 2-s2.0-84866373893 22525606
49 Benlidayi I. C. Guzel R. Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect ISRN Rheumatology 2013 2013 6 215034 10.1155/2013/215034 PMC3671545 23762600
50 Stockmann P. Vairaktaris E. Wehrhan F. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: A prospective clinical study with 12 months follow-up Supportive Care in Cancer 2010 18 4 449 460 2-s2.0-77952503639 10.1007/s00520-009-0688-1 19609572
51 Ruggiero S. L. Emerging Concepts in the Management and Treatment of Osteonecrosis of the Jaw Oral and Maxillofacial Surgery Clinics of North America 2013 25 1 11 20 2-s2.0-84873516261 10.1016/j.coms.2012.10.002 23159218
52 Jabbour Z. El-Hakim M. Mesbah-Ardakani P. Henderson J. E. Albuquerque R. Jr. The outcomes of conservative and surgical treatment of stage 2 bisphosphonate-related osteonecrosis of the jaws: A case series International Journal of Oral and Maxillofacial Surgery 2012 41 11 1404 1409 2-s2.0-84867399290 10.1016/j.ijom.2012.05.012 22704590